

Datasheet: HCA237P

BATCH NUMBER INN1709

Description:	HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX):HRP
Specificity:	OMALIZUMAB DRUG/TARGET COMPLEX
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	AbD20760_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			1/200 - 1/2000

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	IgG concentration 0.1 mg/ml
Immunogen	Omalizumab
Specificity	Human anti omalizumab, clone AbD20760_hlgG1 binds specifically to the omalizumab/IgE (drug/target) complex. The antibody does not recognize free omalizumab or free human IgE. It can be used in bioanalytical assays to detect bound omalizumab or

biosimilar products exclusively.

Clone AbD20760_hlgG1 can be used to develop a pharmacokinetic (PK) antigen capture assay to measure omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in preclinical or clinical samples. This product is in a full immunoglobulin format and is available directly labeled with HRP. The antibody is also available in unlabeled Fab format ([HCA238](#)).

Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.

[View a summary of all anti-omalizumab antibodies](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D = 0.58$ nM by real time, label free molecular interaction analysis on immobilized omalizumab in complex with human IgE.
ELISA	This product may be used in a direct ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE. Protocol: PK antigen capture ELISA to measure bound drug exclusively
References	1. Harth, S. <i>et al.</i> (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. MAbs. 11 (1): 178-190.
Storage	Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Health And Safety	Material Safety Datasheet documentation #10094 available at:

Information <https://www.bio-rad-antibodies.com/SDS/HCA237P>
10094

Licensed Use For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[RECOMBINANT HUMAN IgE KAPPA \(HCA190\)](#)

[RECOMBINANT HUMAN IgE LAMBDA \(HCA171\)](#)

[HUMAN ANTI OMALIZUMAB \(DRUG/TARGET COMPLEX\) \(HCA238\)](#)

[HUMAN ANTI OMALIZUMAB \(HCA236\)](#)

[HUMAN ANTI OMALIZUMAB \(HCA235\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M371664:200612'

Printed on 12 Sep 2024